Socio-demographic and lifestyle factors in a Swiss study of HIV non- progression;Soziodemographie und lebensweise in einer schweizerischen studie zur HIV-nonprogression

Schweizerische Medizinische Wochenschrift

Volumn 129, Issue 39, 1999, Pages 1397-1404

  Kopp, Ch ^a   Lang, St ^a   Von Overbeck, J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

HIV; Lifestyle; Long term survival; Non progression; Socio demography

Indexed keywords

ARTICLE; DISEASE COURSE; FEMALE; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; SOCIOECONOMICS; SURVIVAL RATE; VIRUS INFECTION;

ADULT; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; LIFE STYLE; MALE; SEXUAL BEHAVIOR; SOCIOECONOMIC FACTORS; SURVIVORS; SWITZERLAND;

EID: 0033517557     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Cao Y, Qin L, Zhang L, Safrit J, Ho D. Virologic and immunologic characterization of long-term survivors of Human Immunodeficiency Virus Type 1 infection. N Engl J Med 1995;332:201-8.
2. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, et al. Studies in subjects with long-term nonprogressive Human Immunodeficiency Virus infection. N Engl J Med 1995;332:209-16.
3. Buchbinder SP, Vittinghoff E, Park MS, Elbeik T, Kalams S, Katz M, et al. Long-term non-progression in the San Francisco City Cohort. XI International Conference on AIDS, 1996: Tu.C.553.
4. + cells correlates with the clinical state of HIV-infected individuals. Proc Natl Acad Sci USA 1996; 93:13125-30.
5. Mosier D, Sieburg H. Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol Today 1994;15:332-9.
6. + T cells in human PBL-SCID mice by noncytopathic HIV isolates. Science 1993;260:689-92.
7. Levy JA. HIV pathogenesis and long-term survival. AIDS 1993;7:1401-10.
8. + cell response against human immunodeficiency virus: implications for long-term survival. Proc Natl Acad Sci USA 1995;92:11135-9.
9. + cell anti-HIV activity correlates with clinical state of the infected individual. Clin Invest 1991;87:1462-6.
10. Easterbrook PJ. Non-progression in HIV infection. AIDS 1994;8:1179-82.
11. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance definition for AIDS among adolescents and adults. Morbid Mortal Weekly Rep 1992;41: 1-19.
12. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994;39:387-94.
13. Egger M, Hirschel B, Krancioli P, Sudre P, Wirz M, Elepp M, et al. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: prospective multicentre study. Br Med J 1997;315:1194-9.
14. Bundesamt für Statistik Abteilung Bevölkerung und Beschäftigung. Schweizerische Gesundheitsbefragung 1992/93. Indikatoren (Stand 4. Oktober 1994).
15. Allardice G, McMenamin J, Codere G, Goldberg D. Non progressors among persons infected with HIV in Scotland prior to the end of 1986. XI International Conference on AIDS, 1996: We.C.3475.
16. Strathdee SA, Veugelers PJ, Page-Shafer KA, McNulty A, Moss AR, Schechter MT, et al. Lack of consistency between five definitions of nonprogression in cohorts of HIV-infected seroconverters. AIDS 1996;10:959-65.
17. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
18. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
19. Brauchli P, Reuteler I, Bürki B, Saller R. Anwendung von komplementärmedizinischen Therapien bei HIV/Aids in der Schweiz. Schweiz Med Wochenschr 1996;126:1297-305.
20. Knox T, Speigelmann D, Gorbach S. Vitamin levels in HIV-infected persons. XI International Conference on AIDS, 1996: We.B.3264.
21. Troop M, Easterbrook P, Thornton S, Flynn R, Gazzard B, Catalan J. Reasons given by patients for "non-progression" in HIV infection. AIDS Care 1997;9:133-42.
22. Burns DN, Kramer A, Yellin F, Fuchs D, Wachter H, DiGioia RA, et al. Cigarette smoking: a modifier of Acquired Immunodeficiency Syndrome Type 1 infection? J Acquir Immune Defic Syndr 1991;4:76-83.
23. Park LP, Margolick JB, Giorgi JV, Ferbas J, Bauer K, Kaslow R, et al. Influence of HIV infection and cigarette smoking on leukocyte profiles in homosexual men. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1992;5: 1124-30.
24. Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J, Coulson AC, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. JAMA 1989;261: 3424-9.
25. Coates R, Farewell V, Raboud J, Read S, MacFadden D, Calzavara L. Cofactors of progression to Acquired Immunodeficiency Syndrome in a cohort of male sexual contacts of men with Human Immunodeficiency Virus disease. Am J Epidemiol 1990;132:717-22.
26. Veugelers PJ, Page KA, Tindall B, Schechter MT, Moss AR, Winkelstein WW, et al. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconvertor Study. Am J Epidemiol 1994;140: 747-58.
27. Rigsby LW, Dishman RK, Jackson AW, MacLean GS, Raven PB. Effects of exercise training on men seropositive for the Human Immunodeficiency Virus-1. Med Sci Sports Exerc 1992;24:6-12.
28. Centers for Disease Control and Prevention. Continued sexual risk behavior among HIV-seropositive drug-using men. Morbid Mortal Weekly Rep 1996;45:151-2.
29. Cozzi Lepri A, Pezzotti P, Dorrucci M, Philips AN, Rezza G. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex followed for up to nine years from seroconversion. Br Med J 1994;309: 1537-42.
30. Morlat P, Parneix P, Douard D, Lacoste D, Dupon M, Chene G, et al. Women and HIV infection: a cohort study of 483 HIV-infected women in Bordeaux, France, 1985-1991. AIDS 1992;6:1187-93.
31. Melnick SL, Sherer R, Louis TA, Hillman D, Rodriguez EM, Lackman C, et al. Survival and disease progression according to gender of patients with HIV infection: The Terry Beirn Community Programs for Clinical Research. JAMA 1994; 27:1915-21.
32. Operskalski EA, Stram DO, Lee H, Zhou Y, Donegan E, Busch MP, et al. Human Immunodeficiency Virus Type 1 infection: relationship of risk group and age to rate of progression. J Infect Dis 1995;172:648-55.
33. Prins M, Veugelers P. Comparison of progression and nonprogression among injection drug users and homosexual men with documented dates of HIV-1 seroconversion. XI International Conference on AIDS, 1996: Tu.C.2520.
34. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum E, Klein RS, et al. Clinical manifestations and predictors of disease progression in drug users with Human Immunodeficiency Virus infection. N Engl J Med 1992;327:1697-703.
35. von Overbeck J, Egger M, Smith GD, Schoep M, Ledergerber B, Furrer H, et al. Survival in HIV infection: do sex and category of infection matter? AIDS 1994;8:1307-13.
36. The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS 1992;6:421-6.
37. Ferro S, Salit IE. HIV infection in patients over 55 years of age. J Acquir Immune Defic Syndr 1992;5:348-53.
38. Schechter MT, Hogg RS, Aylward B, Craib KJP, Le TN, Montaner JS. Higher socioeconomic status is associated with slower disease progression of HIV infection independent of access to health care. J Clin Epidemiol 1994;47: 59-67.
39. Ledergerber B, Egger M, Rickenbach M. Poverty and prognosis of HIV infection in Switzerland. AIDS 1998;12: 1933-4.
40. UNAIDS/WHO. Report on the global HIV/AIDS epidemic-June 1998: UNAIDS/WHO, 1998.
41. Centers for Disease Control and Prevention. Trends in AIDS incidence, deaths, and prevalence - United States, 1996. Morbid Mortal Weekly Rep 1997;46:165-71.
42. Hogg RS, Strathdee SS, Craib KJ, Shaughnessy MV, Montaner JS, Schechter MT. Lower socioeconomic status and shorter survival following HIV infection. Lancet 1994;344: 1120-4.
43. Hogg RS, Schechter MT, Schilder A, Le R, Strathdee SA, Goldstone IL, et al. Access to health care and geographic mobility of HIV/AIDS patients. AIDS Patient Care 1995;9: 297-302.
44. Graham NM, Jacobson LP, Kuo V, Chmiel JS, Morgenstern H, Zucconi SL. Access to therapy in the Multicenter AIDS Cohort Study. J Clin Epidemiol 1994;47:1003-12.
45. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763-8.
46. Bassetti S, Battegay M, Furrer H, Rickenhach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J Acquir Immune Defic Syndr Hum Retrovirol 1999;21:114-9.